Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166487 · ClinicalTrials.gov registry record · Phase 2
Plasma-Adapted First-Line Pembro In NSCLC
A Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV, sponsored by Julia K. Rotow, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT04166487 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV that is active but no longer recruiting, run by Julia K. Rotow, MD. The registered enrollment target is 40 participants, below the 392-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT04166487, a Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV, is active but no longer recruiting, sponsored by Julia K. Rotow, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. The names of the study drugs involved in this study are: * Pembrolizumab * Platinum doublet chemotherapy, which may include the following: * Carboplatin and pemetrexed * Carboplatin and paclitaxel The name of the blood test: \- InVision (Inivata, Ltd.)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG PEMETREXED
- DRUG CARBOPLATIN
- DRUG PACLITAXEL
- DIAGNOSTIC_TEST InVision
Study Locations (5)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Boston Medical Center - Boston
- Dana-Farber at Steward St. Elizabeth's Medical Center - Brighton
- Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital - South Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04166487
The ClinicalTrials.gov registry entry for NCT04166487 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Julia K. Rotow, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04166487 reports 5 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04166487 about?
NCT04166487 is a clinical study titled "Plasma-Adapted First-Line Pembro In NSCLC". This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue trea...
What is the current status of trial NCT04166487?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-01-13. Estimated completion is 2026-12-01.
What conditions does trial NCT04166487 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, NSCLC Stage IV.
What interventions are being tested in trial NCT04166487?
The interventions under investigation include: Pembrolizumab (DRUG), PEMETREXED (DRUG), CARBOPLATIN (DRUG), PACLITAXEL (DRUG), InVision (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04166487?
This trial is sponsored by Julia K. Rotow, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04166487 being conducted?
This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Phase 2
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
NSCLC Stage IV
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.